Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer

DOI PDF 14 Citations

Bibliographic Information

Published
2006-01-01
DOI
  • 10.1158/0008-5472.can-05-2749
Publisher
American Association for Cancer Research (AACR)

Search this article

Description

<jats:title>Abstract</jats:title> <jats:p>Activating mutations in receptor tyrosine kinases play a critical role in oncogenesis. Despite evidence that Met kinase is deregulated in human cancer, the role of activating mutations in cancers other than renal papillary carcinoma has not been well defined. Here we report the identification of somatic intronic mutations of Met kinase that lead to an alternatively spliced transcript in lung cancer, which encodes a deletion of the juxtamembrane domain resulting in the loss of Cbl E3-ligase binding. The mutant receptor exhibits decreased ubiquitination and delayed down-regulation correlating with elevated, distinct Met expression in primary tumors harboring the deleted receptor. As a consequence, phospho-Met and downstream mitogen-activated protein kinase activation is sustained on ligand stimulation. Cells expressing the Met deletion reveal enhanced ligand-mediated proliferation and significant in vivo tumor growth. A hepatocyte growth factor competitive Met antagonist inhibits receptor activation and proliferation in tumor cells harboring the Met deletion, suggesting the important role played by ligand-dependent Met activation and the potential for anticancer therapy. These results support a critical role for Met in lung cancer and somatic mutation–driven splicing of an oncogene that leads to a different mechanism for tyrosine kinase activation through altered receptor down-regulation in human cancer. (Cancer Res 2006; 66(1): 283-9)</jats:p>

Journal

  • Cancer Research

    Cancer Research 66 (1), 283-289, 2006-01-01

    American Association for Cancer Research (AACR)

Citations (14)*help

See more

Details 詳細情報について

Report a problem

Back to top